Naloxone in the Treatment of Acute Dissociative States in Female Patients with Borderline Personality Disorder
The DOI matches its Crossref record.
Abstract
BACKGROUND: Acute dissociative states are common in patients with borderline personality disorder (BPD). However, there are no established pharmacotherapeutic treatment options for this severe clinical condition. METHODS: The effect of 0.4 mg naloxone administered intravenously in acute dissociative states was examined as compared to placebo in a double-blind crossover study in nine patients who met DSM-IV-criteria for BPD. Dissociative symptoms before and 15 min after a single dose of naloxone or saline placebo were assessed using a self-rating instrument for dissociation and aversive inner tension (DSS) and the observer-based items of the Clinician Administered Dissociative States Scale (CADSS). RESULTS: Dissociative symptoms before treatment with naloxone or saline placebo were moderate to severe. After injection of either naloxone or placebo, dissociative symptoms significantly decreased on the DSS (p < 0.01) and the CADSS (p < 0.05). However, there were no significant differences between naloxone and placebo in the reduction of symptoms. Patients who showed the most prominent response to naloxone fulfilled the highest number of DSM-IV-criteria for BPD. CONCLUSIONS: Although it is difficult to draw definite conclusions from this small sample of patients, this study does not support the assumption that naloxone in a single dose of 0.4 mg is superior to placebo in acute dissociative states in patients with BPD. Further studies will investigate whether patients benefit from naloxone in a higher dose or whether subgroups of patients with BPD profit from naloxone in acute dissociative states.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cited by
Lanius, R. A., Brand, B., Vermetten, E., Frewen, P. A., & Spiegel, D. (2012) · Depression and Anxiety · doi:10.1002/da.21889 · Cited by 459
“[38] Opioid antagonists, including naltrexone and naloxone also have been explored as a pharmacotherapeutic treatment option for dissociative symptomatology.[39, 40] However, there have been few placebo-controlled pharmacotherapeutic trials for dissociative symptoms, and no specific antidissociative drugs have been de…”
BackgroundPharmacological interventions for borderline personality disorder
Stoffers, J., Völlm, B. A., Rücker, G., Timmer, A., Huband, N., & Lieb, K. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005653.pub2 · Cited by 302
Self-citationBorderline personality disorder: a dysregulation of the endogenous opioid system?
Bandelow, B., Schmahl, C., Falkai, P., & Wedekind, D. (2010) · Psychological Review · doi:10.1037/a0018095 · Cited by 135
Ludäscher, P., Valerius, G., Stiglmayr, C., Mauchnik, J., Lanius, R. A., Bohus, M., & Schmahl, C. (2010) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.090022 · Cited by 131
Self-citationDuggan, C., Huband, N., Smailagic, N., Ferriter, M., & Adams, C. (2007) · Personality and Mental Health · doi:10.1002/pmh.22 · Cited by 117
Pharmacotherapy for Borderline Personality Disorder—Current Evidence and Recent Trends
Stoffers‐Winterling, J., & Lieb, K. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-014-0534-0 · Cited by 130
Self-citationMcKinnon, M. C., Boyd, J. E., Frewen, P. A., Lanius, U. F., Jetly, R., Richardson, J. D., & Lanius, R. A. (2016) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2016.07.017 · Cited by 94
Endogenous opiates and behavior: 2004
Bodnar, R. J., & Klein, G. E. (2005) · Peptides · doi:10.1016/j.peptides.2005.06.010 · Cited by 101
Evidence-based pharmacotherapy for personality disorders
Ripoll, L. H., Triebwasser, J., & Siever, L. J. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000071 · Cited by 83
“Although tension, dissociative symptoms, self-injurious urges, and suicidal ideation decreased for both doses, there was no difference between the two doses (Philipsen et al. 2004a).”
BackgroundMethodInfluentialDevelopment and Psychometric Characteristics of the Dissociation Tension Scale
Stiglmayr, C., Schimke, P., Wagner, T., Braakmann, D., Schweiger, U., Sipos, V., Fydrich, T., Schmahl, C., Ebner-Priemer, U., Kleindienst, N., et al. (2010) · Journal of Personality Assessment · doi:10.1080/00223891003670232 · Cited by 80
“State-related instruments such as CADSS, SODAS, SSD, or DSS-acute are particularly suited for recording short-term changes of dissociative symptoms through specific interventions, for example, during psychopharmacological ( Philipsen, Schmahl, & Lieb, 2004 ), psychophysiological ( Ludascher et al, 2007 ), or neurobiol…”
Self-citationPatients with Borderline Personality Disorder in Emergency Departments
Shaikh, U., Qamar, I., Jafry, F., Hassan, M., Shagufta, S., Odhejo, Y. I., & Ahmed, S. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00136 · Cited by 92
“(69) An open label study 14 females with acute states of strong aversive inner tension and urge to commit self-injurious behavior 75 and 150 μg of oral clonidine After administration of clonidine in both doses, aversive inner tension, dissociative symptoms, urge to commit self-injurious behavior, and suicidal ideation…”
BackgroundDepersonalization disorder: pharmacological approaches
Sierra, M. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.1.19 · Cited by 62
Psychopharmacologic treatment of borderline personality disorder
Ripoll, L. H. (2013) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2013.15.2/lripoll · Cited by 54
Warrender, D., Bain, H., Murray, I., & Kennedy, C. M. (2020) · Journal of Psychiatric and Mental Health Nursing · doi:10.1111/jpm.12637 · Cited by 68
“Naloxone (0.4 mg) administered intravenously showed improvement in dissociative symptoms, though was not better than placebo (Philipsen et al., 2004).”
BackgroundInfluentialBozzatello, P., Rocca, P., Rosa, M. L. D., & Bellino, S. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1686482 · Cited by 64
“Among opiate antagonists, naloxone and naltrexone were not found to be superior to placebo in treating acute dissociative states in patients with BPD in two small placebocontrolled studies [110,111].”
BackgroundKolla, N. J., Eisenberg, H., & Links, P. S. (2008) · Archives of Suicide Research · doi:10.1080/13811110701542010 · Cited by 46
“…opiate systems could be responsible for impairments of perception observed in patients with BPD. Continuing along this same line of inquiry, Philipsen, Schmahl, and Lieb (2004) tested that ability of intravenous naloxone, an opioid antagonist, to reduce symptom burden in patients…”
BackgroundMagerl, W., Burkart, D., Fernandez, A., Schmidt, L. G., & Treede, R.-D. (2012) · Pain · doi:10.1016/j.pain.2011.11.021 · Cited by 43
“The opioid antagonists naltrexone and naloxone reduced analgesia in BPD, however, placebo was equally effective [7,60,67], not supporting a specific opioid involvement.”
BackgroundDuggan, C., Huband, N., Smailagic, N., Ferriter, M., & Adams, C. (2008) · Personality and Mental Health · doi:10.1002/pmh.41 · Cited by 44
Pharmacotherapy for dissociative disorders: A systematic review
Sutar, R., & Sahu, S. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.112529 · Cited by 42
Possible role of a dysregulation of the endogenous opioid system in antisocial personality disorder
Bandelow, B., & Wedekind, D. (2015) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2497 · Cited by 41
Dissociation in the Binge–Purge Cycle of Bulimia Nervosa
McShane, J. M., & Zirkel, S. (2008) · Journal of Trauma & Dissociation · doi:10.1080/15299730802225680 · Cited by 35
Ripoll, L. H. (2011) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32834c3f19 · Cited by 37
“Nevertheless, opioid agonists [81,82] and antagonists [83] have been ineffective and potentially detrimental (mainly due to risks of dependence or overdose) in treating BPD patients.”
BackgroundReutens, S. G., Nielsen, O., & Sachdev, P. S. (2010) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e3283387ab4 · Cited by 37
Pharmacotherapy of Borderline Personality Disorder: A Systematic Review
Bellino, S., Rinaldi, C., Bozzatello, P., & Bogetto, F. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711796504682 · Cited by 30
Pharmacological treatments for personality disorders
Paris, J. (2011) · International Review of Psychiatry · doi:10.3109/09540261.2011.586993 · Cited by 27
Current Clinical Psychopharmacology in Borderline Personality Disorder
CASALE, A. D., Bonanni, L., Bargagna, P., Novelli, F., Fiaschè, F., Paolini, M., Forcina, F., Anibaldi, G., Cortese, F. N., Iannuccelli, A., et al. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210610092958 · Cited by 34
“Philipsen et al., 2004 [110] CLN (75-150 mcg) Interventional Study (1 Day) 14 (0, 14) 28.7 (6.9) Major depressive disorder, trichotillomania, bulimia, alcohol abuse, agoraphobia, obses- sivecompulsive disorder no DES, heart rate, blood pressure Aversive inner tension, dissociative…”
BackgroundInfluentialPharmacotherapy of personality disorders
Triebwasser, J., & Siever, L. J. (2007) · Journal of Mental Health · doi:10.1080/09638230601182078 · Cited by 26
“Moreover, several studies have shown a high degree of placebo responsiveness in this disorder (e.g., Philipsen et al., 2004b; Salzman et al., 1995; Schulz et al., 1999).”
BackgroundMethodOff-label use of atypical antipsychotics in personality disorders
Rosenbluth, M. J., & Sinyor, M. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.608351 · Cited by 26
“Single openlabel studies of the opioid antagonists naloxone [71] and naltrexone [72] as well as the a2 agonist clonidine [73] have demonstrated possible efficacy in treating dissociative symptoms in BPD.”
BackgroundRiegel, K. D., Ksinan, A. J., & Schlosserová, L. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.643270 · Cited by 23
“, borderline and impulsive) on the Psychoticism domain confirms the clinical experience with the quasi-psychotic phenomena and transient dissociative states in this group of patients (55, 56).”
ResultTreatment of dissociative identity disorder: leveraging neurobiology to optimize success
Purcell, J. B., Brand, B., Browne, H. A., Chefetz, R. A., Shanahan, M., Bair, Z. A., Baranowski, K. A., Davis, V., Mangones, P., Modell, R. L., et al. (2024) · Expert review of neurotherapeutics · doi:10.1080/14737175.2024.2316153 · Cited by 18
“For example, neither naloxone nor naltrexone performed better than placebo for dissociative symptoms in randomized controlled trials in borderline personality disorder samples [119,120].”
BackgroundBurback, L., Forner, C. C., Winkler, O., Al-Shamali, H. F., Ayoub, Y., Paquet, J., & Verghese, M. (2024) · Psychology Research and Behavior Management · doi:10.2147/prbm.s402456 · Cited by 16
Psychopharmacologic Management of Suicidality in Personality Disorders
Cardish, R. J. (2007) · The Canadian Journal of Psychiatry · doi:10.1177/07067437070526s110 · Cited by 15
“77 There was significant reduction on symptoms of dissociation and “aversive inner tension” after injection, with no difference between naloxone and placebo.”
Treatment of dissociative symptoms with opioid antagonists: a systematic review
Escamilla, I., Juan, N., Peñalva, C., Sánchez-Llorens, M., Renau, J., Benito, A., & Haro, G. (2023) · European Journal of Psychotraumatology · doi:10.1080/20008066.2023.2265184 · Cited by 15
“However, Philipsen et al. (2004) support that pain has an anti-dissociative e ff ect, agree with the anti-dissociative model that emphasises the role of pain to generate bodily sensations to maintain contact with reality (Klonsky, 2007).”
BackgroundResultMedications in the treatment of borderline personality disorder 2006
Mercer, D. (2007) · Current Psychiatry Reports · doi:10.1007/s11920-007-0010-1 · Cited by 10
Pharmacotherapy of severe personality disorders: a critical review
Rinne, T., & Ingenhoven, T. (2007) · Cambridge University Press eBooks · doi:10.1017/cbo9780511544439.010 · Cited by 9
Bremner, J. D., Williamson, D., & Vaccarino, V. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.08.050 · Cited by 9
Borderline personality disorder - a dysregulation of the endogenous opioid system?
Bandelow, B., Schmahl, C. G., Falkai, P., & Wedekind, D. (2011) · European Psychiatry · doi:10.1016/s0924-9338(11)72713-4 · Cited by 8
Self-citationPharmacotherapy of personality disorders: what we know and what we have to search for
Bozzatello, P., Ghirardini, C., Uscinska, M., Rocca, P., & Bellino, S. (2017) · Future Neurology · doi:10.2217/fnl-2017-0010 · Cited by 8
“14 One small double-blind study [95] including 9 BPD patients failed to show the efficacy of i.”
BackgroundPharmacotherapy in the Collaborative Treatment of Trauma‐Induced Dissociation and Psychosis
Rudegeair, T., & Farrelly, S. (2008) · Wiley eBooks · doi:10.1002/9780470699652.ch22 · Cited by 7
Recent evidence-based developments in the treatment of DID
Bachrach, N., & Huntjens, R. J. C. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1650164 · Cited by 11
“…blind randomized controlled trials among individuals with borderline personality disorder found no superiority of naloxone or naltrexone over placebo in reduction of dissociative symptoms (91, 92), and naloxone did not block ketamine-induced dissociation in a double-blind crossover study (93).”
Evidence-based pharmacotherapy of personality disorders
Ripoll, L. H., Triebwasser, J., & Siever, L. J. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511910395.015 · Cited by 6
Recent approaches to pharmacotherapy of personality disorders
Bellino, S., Rinaldi, C., Bozzatello, P., & Bogetto, F. (2011) · Neuropsychiatry · doi:10.2217/npy.11.17 · Cited by 6
Wöckel, L., Goth, K., Matic, N., Zepf, F. D., Holtmann, M. H., & Poustka, F. (2009) · Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie · doi:10.1024/1422-4917.a000005 · Cited by 6
Pharmakologische und psycho- therapeutische Behandlung der Borderline-Störung
Remmel, A., & Bohus, M. (2006) · Zeitschrift für Psychiatrie Psychologie und Psychotherapie · doi:10.1024/1661-4747.54.3.185 · Cited by 11
Uscinska, M., & Bellino, S. (2018) · Future Neurology · doi:10.2217/fnl-2018-0006 · Cited by 6
Farmacotherapie persoonlijkheidsstoornissen
Ingenhoven, T., & Rinne, T. (2017) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-368-0931-3_20 · Cited by 3
Ingenhoven, T., & Rinne, T. (2009) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-313-6821-1_19 · Cited by 2
Evidence-Based Pharmacotherapy for Personality Disorders
Ripoll, L. H., Triebwasser, J., & Siever, L. J. (2013) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.11.2.225 · Cited by 2
Kapfhammer, H. (2017) · Springer eBooks · doi:10.1007/978-3-662-49295-6_73 · Cited by 2
Pharmacology of Personality Disorders
Triebwasser, J., & Siever, L. J. (2006) · Cited by 2
Kapfhammer, H. (2011) · Springer eBooks · doi:10.1007/978-3-642-03637-8_60 · Cited by 2
Towards a pharmacology of depersonalization
Sierra, M. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9780511730023.009 · Cited by 1
Schmahl, C. G. (2009) · Springer eBooks · doi:10.1007/978-3-540-88489-7_4 · Cited by 1
Self-citationGarcía, M. C. (2019) · Vertex Revista Argentina de Psiquiatría · doi:10.53680/vertex.v30i148.122 · Cited by 3
“dad del TLP siendo mayor en los pacientes que cumplan más criterios diagnósticos por DSM (11, 12).”
BackgroundInfluentialFreyberger, H. J., & Spitzer, C. (2012) · Springer eBooks · doi:10.1007/978-3-642-29897-4_17 · Cited by 1
Advances in Treatment for Personality Disorders
Biskin, R. S., & Paris, J. (2018) · Springer eBooks · doi:10.1007/978-3-319-70554-5_19 · Cited by 1
Gillavry, D. W. M., & Ullrich, D. C. (2020) · Military Psychology · doi:10.1080/08995605.2020.1730111 · Cited by 1
Ingenhoven, T., & Rinne, T. (2007) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-313-6404-6_18 · Cited by 1
Persönlichkeitsstörungen im Spannungsfeld zwischen Biologie und Sozialisation (ICD-10 F6)
Fiedler, P. A., & Herpertz, S. C. (2012) · Elsevier eBooks · doi:10.1016/b978-3-437-24903-7.10019-8
Nuss, M. (2016) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-5549
Guideline Development Group Membership
Tyrer, P. J., Kendall, T., BATEMAN, A. W., Psychiatrist, C., Bayliss, L., & Bouras, N. (2005)
Persönlichkeitsstörungen im Spannungsfeld zwischen Biologie und Sozialisation (ICD-10 F6)
Fiedler, P. A., & Herpertz, S. C. (2009) · Elsevier eBooks · doi:10.1016/b978-3-437-24900-6.50021-6
Psychopharmacologie du trouble de la personnalité borderline
Perroud, N. A. (2019) · Elsevier eBooks · doi:10.1016/b978-2-294-76266-6.00010-0
Persönlichkeitsstörungen im Spannungsfeld zwischen Biologie und Sozialisation (ICD-10 F6)
Fiedler, P. A., & Herpertz, S. C. (2006) · Elsevier eBooks · doi:10.1016/b978-343724130-7.50016-x
Current awareness in human psychopharmacology
(2005) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.634
Schmahl, C. G. (2013) · Springer eBooks · doi:10.1007/978-3-642-35068-9_4
Self-citationSchmahl, C. G. (2019) · Springer eBooks · doi:10.1007/978-3-662-58470-5_6 · Cited by 1
Self-citationKapfhammer, H. (2016) · Springer eBooks · doi:10.1007/978-3-642-45028-0_73-1
(2013) · CRC Press eBooks · doi:10.1201/b15462-35
ДЕПЕРСОНАЛІЗАЦІЙНО-ДЕРЕАЛІЗАЦІЙНИЙ РОЗЛАД: СУЧАСНІ УЯВЛЕННЯ
КОБЗАР, О., & ПИЛЯГІНА, Г. (2022) · Психологічне здоров’я · doi:10.32689/2663-0672-2021-1-3 · Cited by 1
Schmahl, C. G. (2022) · Springer eBooks · doi:10.1007/978-3-662-64057-9_6
Self-citationPharmakotherapeutische Ansätze
Priebe, K., Schmahl, C. G., & Stiglmayr, C. (2013) · Springer eBooks · doi:10.1007/978-3-642-35066-5_9
Self-citationPriebe, K., Schmahl, C. G., & Stiglmayr, C. (2013) · Springer eBooks · doi:10.1007/978-3-642-35066-5_3
Self-citationLawrence, O. C., Goncearenco, I., & Ziafat, K. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780197582718.003.0005
Chapter 56. Treatment of Personality Disorders
Hollander, E., Vats, T., & Desilva, N. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as56
Miño-Reyes, V., Larenas-Matta, P., Quijada-Leyton, M. J., & Nvo-Fernández, M. (2026) · European Journal of Trauma & Dissociation · doi:10.1016/j.ejtd.2026.100763 · Cited by 1
Metadata
- Authors
- Philipsen, A., Schmahl, C., & Lieb, K.
- Affiliations
- University of Freiburg (DE)
- Venue
- Pharmacopsychiatry
- Publisher
- Georg Thieme Verlag KG
- Published
- 2004-09
- Volume
- 37
- Issue
- 5
- Pages
- 196-199
- ISSN
- 0176-3679 (ISSN-L)
- 1439-0795
- OpenAlex
- W2009952140
- Cited by
- 80
- References
- 0
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 4 · 2023: 2 · 2022: 1 · 2021: 3 · 2020: 2 · 2019: 6 · 2018: 2 · 2017: 5 · 2016: 3 · 2015: 1 · 2014: 2 · 2013: 7 · 2012: 4
- FWCI
- 5.20
- Type
- journal article
- Language
- de
- Open access
- closed
- Locations
- Pharmacopsychiatry (publishedVersion)
- PubMed (publishedVersion)
- FreiDok plus (Universitätsbibliothek Freiburg) (submittedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Personality Disorders and Psychopathology
- Health Sciences › Medicine › Psychiatry and Mental health › Psychosomatic Disorders and Their Treatments
- Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
- Keywords
- naloxone, borderline personality disorder, dissociative states, female patients, intravenous administration, dissociation, placebo comparison, pharmacotherapy
- MeSH terms
- Acute Disease, Adult, Borderline Personality Disorder, Dissociative Disorders, Double-Blind Method, Female, Humans, Injections, Intravenous, Naloxone, Narcotic Antagonists, Severity of Illness Index, Cross-Over Studies, Diagnostic and Statistical Manual of Mental Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.